indicating the importance of MHC antigens in anti-tumour responses are not confirmed by the analysis of cancer patient survival data.
The classical class I genes HLA-A, HLA-B and HLA-C encode for an a-chain which associates with P2-microglobulin (02m) to be expressed on the cell membrane. Class II genes are subdivided into the subregions HLA-DR, -DQ and -DP which encode for cx/p heterodimeric membrane antigens (Guillemot et al., 1988) . MHC class I antigens are expressed on the majority of normal nucleated cells (Daar et al., 1984a) whereas the distribution of class II antigens in normal tissues is more restricted (Daar et al., 1984b) . The physiological role of MHC antigens lies in their restrictive function for T-cell immune recognition and immune response. CD4 positive Tcell subsets recognise antigen in the context of MHC class II molecules, CD8 positive cells in association with MHC class I antigens (Hedrick, 1988) .
Based on animal tumour models there is ample evidence that the loss of MHC class I antigen expression allows tumour growth and metastasis formation by escape from T-cell mediated surveillance (Doherty et al., 1984; Hammerling et al., 1987; Tanaka et al., 1988) . The involvement of MHC class I antigens in the in vitro lysis of tumour cells by specific cytotoxic T-lymphocytes is well documented (Anichini et al., 1985; V'anky, 1986; Roberts et al., 1987; V'anky et al., 1987; Itoh et al., 1988; Darrow et al., 1989; Knuth et al., 1989) .
Less is known about the immunological implications of MHC class II expression on tumour cells. In vitro assays, using autologous fresh tumour cells to stimulate peripheral blood lymphocytes, indicated that the presence of HLA-DR antigens was not related to the proliferative response of the lymphocytes for a variety of malignomas (Vanky et al., 1985; Vanky, 1986) and for ovarian carcinomas (Di Bello et al., 1988) . In primary malignant melanomas (not included in the series of Vatnky) the induction of proliferation correlated with the expression of HLA-DR on fresh tumour cells and could be blocked by anti-HLA-DR antibodies. In contrast, metastatic melanomas induced proliferative responses in a minority of cases only (Fossati et al., 1984; Parmiani et al., 1985) . Using melanoma cell lines established from early and advanced disease, Guerry et al. (1984) reported on the HLA-DR dependent stimulation of lymphocytes by early stage melanomas whereas advanced melanomas failed to induce proliferation.
MHC antigens have repeatedly been demonstrated in human breast tumours (Fleming et al., 1981; Natali et al., 1981 Natali et al., , 1983 Natali et al., , 1984 Natali et al., , 1986 Weiss et al., 1981; Bhan & DesMarais, 1983; Rowe & Beverley, 1984; Sawtell et al., 1984; Sidky & Walker, 1984; Whitwell et al., 1984; Gottlinger et al., 1985; Hurlimann & Saraga, 1985; Perez et al., 1986; Zuk & Walker, 1987; Muller & Stutte, 1988) . Sawtell et al. (1984) found a correlation between the histological, not cytological, tumour differentiation and the expression of P2m and MHC class I antigens. Sidky & Walker (1984) observed that histologically poorly differentiated carcinomas stained less for P2m- Zuk & Walker (1987) demonstrated a correlation between tumour grading and the expression of P2m and HLA-A,B,C. Regarding the prognostic value of tumour grading for breast cancer patients (Bloom & Richardson, 1957; Freedman et al., 1979; Haybittle et al., 1982; Reiner et al., 1985; Russo et al., 1987; Chevallier et al., 1988) (UICC, 1987;  Table I ). Immunoperoxidase staining The sections were thawed, fixed in acetone for 10 min at RT and rehydrated in PBS (0.04 M, pH 7.4). They were incubated with the first antibody for 30 min at 37°C, then with the second biotinylated horse anti-mouse IgG for 30 min at RT and finally with the ABC for 45 min at RT. After each incubation step the sections were washed three times in PBS. Peroxidase was visualised with DAB in 0.06% hydrogen peroxide. The colour of the DAB precipitation product was intensified by 0.5% copper sulphate in physiological saline. The sections were counterstained with hematoxylin. Negative controls were carried out by replacing the primary antibody by PBS. Stromal cells which were ubiquitously present served as intrinsic positive controls for the immunoreactivity of the MoAbs. Blocking of endogenous peroxidase activity was not necessary since endogenous peroxidase activity, if present at all, did not interfere with the interpretation of the specific staining results.
Interpretation of immunohistological results
In order to evaluate the antigen expression in a semiquantitative manner, the following score was applied:
No staining (-); slight staining irrespective of the number of positive tumour (or epithelial) cells, or moderate to strong staining of less than one third of the cells (+); moderate staining of more than one third of the cells, or strong staining of one to two thirds of the cells (+ +); strong staining of more than two thirds of the cells
(+ + +). If residual non-neoplastic epithelial structures
were found in the carcinoma sections they were evaluated separately.
Follow-up Follow-up data of patients with malignancies were collected by means of inquiries of the treating physicians and by review of the medical records of the Surgical Ambulance, Evangelisches Diakoniekrankenhaus, and the Department of Radiotherapy, University of Freiburg. Patients with distant metastases at the time of diagnosis or whose M-status was unknown were excluded from the follow-up (n = 6). Information was retained about the vital status, recurrence of cancer and the cause of death. The date of histopathological diagnosis of the carcinoma was regarded as the start of followup. Data (n = 54) include the date of the last observation of patients alive or the date of death from patients who died from causes other than carcinoma, or from those whose cause of death was unknown. For five patients no information about their postsurgical status could be obtained; they were not considered for the analysis of overall survival. For the analysis of disease-free survival 48 cases provided data. Six patients for whom no information on the relapse was available were excluded. The follow-up time ranged from 26 to 81 months (median 45 months).
Statistical methods
The statistical analysis of the data was performed by the Department of Medical Biometrics and Medical Informatics, University of Freiburg. To check for correlations between the expression of MHC antigens and the histological type of lesions and to test the difference in staining results between benign and malignant tumours the x2 test was used, while the Sign test was employed to correlate antigen expression in tumor cells with the expression in residual non-neoplastic epithelium. Survival curves were estimated according to Kaplan-Meier and the log-rank, Wilcoxon and the likelihood ratio test were applied as tests of significance. The computing was done by the SAS procedure LIFETEST. The identification of independent prognostic effects of MHC antigen expression was assessed by the Cox multivariate regression analysis. The characteristics which were included were the pT-stage grouped in two categories, Ti -2 and T3-4; two groups formed according to the number of axillary lymph node metastases; and those without, or with up to 3, and those with more than 3 positive nodes. Carcinomas were classified as hormone receptor positive or negative. The age of patients was included as a continuous variable. If any of the above information was not available, patients were excluded, resulting in 63 patients studied for overall and 62 patients for disease-free survival. The Cox regression analysis was computed with BMDP2L, from BMDP Statistical Software, Los Angeles, California. The computing comprised the elimination of single covariates tested against the complete model as well as stepwise-up and stepwise-down regressions. To test for significance the Wald, likelihood ratio, score and x2 test were applied.
Results

Immunohistology
The staining results of the benign breast lesions are summarised in Table III expression the patients were classified into three groups: -and + (n = 25); + + (n = 26); + + + (n=15). For HLA-A,B,C the following classes were formed: -(n = 16); + (n = 36); + + and + + + (n = 14). HLA-DR expression resulted in two classes: -(n = 57); + and + + (n = 9). None of these 3 parameters produced significant differences in the survival curves ( Figure 5 ).
Disease-free survival In contrast to overall survival, the pTstage influenced disease-free survival in our cohort (P <0.01). Axillary lymph node status (P <0.01) and hormone receptor status (P <0.05) also resulted in significantly different disease-free survival curves. Patients with smaller tumours, less than 4 axillary lymph node metastases or hormone receptor positive carcinomas, showed a more favourable prognosis. No effect of P2m, HLA-A,B,C or HLA-DR expression on disease-free survival was observed using the same classification of patients as for overall survival ( Figure 6 ).
Cox analysis To exclude the theoretical possibility that the effect of antigen expression in the Kaplan-Meier estimates was covered by other factors Cox multivariate regression analyses were carried out. The Cox analysis of overall survival data resulted in only two variables being of prognsotic importance irrespective of the computing method, i.e., the number of axillary lymph nodes (P <0.01) and the hormone receptor status (P <0.01). For the disease-free survival data, no effect of MHC expression was seen. Again, the number of positive axillary lymph nodes (P<0.05) and the hormone receptor status (P <0.05) were of importance, together with the pT-stage, only in the stepwise-up regression (P<0.01). The high expression of HLA-A,B,C and P2m and a lower expression of HLA-DR in benign lesions are in concordance with the results of other studies (Weiss et al., 1981; Bhan & DesMarais, 1983; Rowe & Beverley, 1984; Sidky & Walker, 1984; Whitwell et al., 1984; Zuk & Walker, 1987) and correspond to the demonstration of these antigens in normal human breast tissue (Daar et al., 1984a (Daar et al., , 1984b Natali et al., 1983) . Likewise, the reduction in expression of MHC antigens and P2m in malignant breast tumours has been already described by other authors (Fleming et al., 1981; Natali et al., 1981 Natali et al., , 1983 Natali et al., , 1984 Bhan & DesMarais, 1983; Rowe & Beverley, 1984; Sawtell et al., 1984; Sidky & Walker, 1984; Whitwell et al., 1984; Gottlinger et al., 1985; Hurlimann & Saraga, 1985; Perez et al., 1986; Zuk & Walker, 1987) , however the positivity rates of the carcinomas in these studies vary considerably. The different MoAbs and methods applied, other criteria for interpretation of staining results and the heterogeneous patterns of antigen expression might explain the divergent results. The expression, or absence, of MHC antigens in breast carcinomas did not apparently influence the overall, or disease-free, survival. The structure of our cohort for age and tumour features is comparable to that of the studies by Shek & Godolphin (1988) and Alexieva-Figusch et al. (1988) , who described the prognostic relevance of the classic parameters such as tumour size, axillary lymph node status, ER and PR levels. This comparability weakens the possible explanation of our results being merely an outcome of a selective collection of patients. In addition, our follow-up period is almost identical to that of Alexieva-Figusch et al., exact data are not given by Shek & Godolphin. The reliability of our results is further strengthened by the identification of the axillary lymph node and hormone receptor status as independent prognostic factors for overall and disease-free survival. These parameters confirm the observations of the studies cited above as well as those from other investigations (Nemoto et al., 1980; Baak et al., 1985; Bryan et al., 1986; Fisher et al., 1987; Russo et al., 1987; Todd et al., 1987; Chevallier et al., 1988) .
Discussion
In colorectal, but not in breast, carcinomas Stein et al. (1988) could not find any influence of MHC antigens on survival. Interestingly, this group described an inverse correlation between the expression of HLA-A,B,C antigens and the degree of differentiation in these carcinomas (Momburg et al., 1986) . Poorly differentiated carcinomas are characterised by a worse clinical prognosis (Morson & Dawson, 1979) . Thus, it seems that a similar discrepancy may also exist for breast carcinomas. The correlation between the reduction in MHC class I antigen expression and poor tumour differentiation, a bad prognostic feature by itself, favours the assumption that loss of MHC class I antigen may impair prognosis. However, this idea is not confirmed by survival analysis.
Several other aspects have to be considered before a prognostic relevance of MHC antigens in breast carcinomas can be excluded. From our study the possibility cannot be ruled out that immunological mechanisms may be important in the regulation of tumour growth of carcinoma subgroups, e.g., carcinomas of small size. Vanky et al. (1983b) and Klein (1988) reported that, in an in vitro assay, tumour cells from patients without metastases were lysed by autologous peripheral blood lymphocytes but not by cells of patients with metastases, and this antitumour reactivity correlated with the survival of the tumour patients (Vafnky et al., 1983a,b) . In melanoma, Brocker et al. (1985) observed shorter disease-free intervals in the case of patients with stage I tumours positive for HLA-DR, while Fossati et al. (1986) could not detect a correlation between the presence of HLA-DR and survival in stage II disease. In vitro tests seem to indicate that MHC class I antigen expression on tumour cells is more relevant for putative in vivo tumour cytotoxicity by T-cells than class II antigens. The differential expression of MHC class I antigens has recently been described in colorectal carcinomas (Rees et al., 1988; Smith et al., 1988; LopezNevot et al., 1989; Momburg et al., 1989) , gastric and laryngeal carcinomas (Lopez-Nevot et al., 1989) and breast carcinomas (Muller & Stutte, 1988 ). An impact of MHC class I subtypes on the clinical course of human breast carcinomas is suggested by the latter group, who demonstrated that HLA-A2 expression in breast carcinomas is conversely related to the number of axillary lymph node metastases. When the same tumours were stained with a MoAb specific for HLA-A,B such a correlation was not found. From these results it was concluded that HLA-B expression reduced the immunogenicity of breast carcinomas which resulted in a higher frequency of metastases. Similar results concerning the MHC class I antigens were reported by Eisenbach et al. (1983 Eisenbach et al. ( , 1984 Eisenbach et al. ( , 1985 based on a mouse tumour model: the imbalance of H-2K/H-2D in favour of H-2D enhanced the metastatic capacity of the tumour cells.
In appraising the relevance of MHC class II expression on tumour cells, it is interesting to note that these antigens have also been correlated with suppressive effects . Although there is little information on the genetics of suppression in man, suppressive phenomena seem to be associated with HLA-DQ (Oliveira & Mitchinson, 1989) . For 6 breast carcinomas the differential expression of MHC class II antigens has been described by Natali et al. (1986) . In patients with metastatic melanoma the same authors observed a more favourable prognosis when the metastases expressed HLA-DQ, which does not fit with the association of HLA-DQ and a supposed suppression of immune response as mentioned above.
The experimental results providing strong evidence for the importance of MHC antigen expression on tumour cells for an effective antitumour immune defence against tumour cell growth are not confirmed by our analysis of tumour patients survival data. However, for breast carcinoma patients' surveillance, our follow-up period is relatively short, since recurrences may appear even after 20 years. In addition, the percentage of data for the Kaplan-Meier estimates was rather high (around 70%). The identification of nodal and hormone receptor status as prognostic parameters in our cohort and the comparison of our median follow-up period with other studies proved that this interval was, nevertheless, long enough for reliable interpretations. However, the study of larger numbers of carcinoma patients and a longer follow-up period are necessary to draw definitive conclusions. BHAN, A.K. & DESMARAIS, C.L. (1983 
